Calgary, Alberta – June 25, 2024 – TheNewswire – nDatalyze Corp. (“NDAT” or the “Corporation”) (CSE:NDAT) (OTC:NDATF) is pleased to update the operations of its 100%-owned Mindbalanced, Inc. subsidiary.

 

The following is for operational update purposes only and is not necessarily material.

 

Joshua Hill, NDAT and Mindbalanced Inc. President, reports: “Our overall solution involves collaborative partnerships with mental health-related facilities, clinics, and clinicians seeking effective and personalized treatment plans for drug-resistant patients. We consult with the entire program, and our revenue-sharing business model benefits customers by saving time, providing state-of-the-art tools, offering personalized treatment protocols, and adding an additional revenue stream. We anticipate significant growth in revenues from private and public medical insurance programs as mental health benefits are incorporated into more insurance plans. Lastly, we anticipate adding substantial biometric, DNA, and TMS treatment response data to our database. This data will be instrumental in advancing clinical research and developing personalized treatment protocols, ultimately leading to improved patient outcomes.”

 

Mindbalanced’s current sales pipeline includes two large healthcare facilities in the Southeast US catering to a patient base of over 2,000 candidates; a major psychiatric hospital in South Florida; and a partnering network in Alabama that serves over 10,000 active patients. The “prospect-to-revenue” cycle is expected to be approximately 120 days with Mindbalanced being well into the cycle with multiple prospects. While none of these prospects are yet under contract they are disclosed to inform investors as to what Mindbalanced’s prospecting activity looks like.

 

Joshua Hill, NDAT and Mindbalanced Inc. President, adds: Leading manufacturers of TMS often use a consumable model that imposes a significant financial strain on facilities thereby reducing patient access to these treatments. In contrast, our non-consumable model means facilities do not pay per treatment, making TMS more accessible and affordable for patients. Our aim is to onboard and launch a new facility every thirty days. This strategy allows the implementation team time to thoroughly consult with potential partners and their staff, ensuring a seamless and effective integration of Mindbalanced’s TMS programs.”

 

For Further Information, please contact:

 

Joshua Hill, President

Email: josh@mindbalanced.org

Tel: (786) 714-4811    

Mindbalanced Website: https://mindbalanced.org

YMI Website: https://ymihealth.ca

nDatalyze Website: https://www.ndatalyze.com      

About Mindbalanced, Inc.: Mindbalanced’s vision is to redefine mental healthcare through an integrative, personalized approach leveraging cutting edge technology and non-invasive treatment protocols. By harnessing evidence-based data we aim to predict and enhance mental wellbeing, taking into account individual predispositions and environmental factors thereby fostering healthier and more fulfilling lives for all.

 

About YMI: YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge towards a fuller understanding of how mental health develops, and how to improve mental wellbeing. YMI combines supervised machine-learning with a proprietary Reference Database to predict an individual’s predisposition toward a variety of common mental conditions, both current and forward in time. YMI is poised to revolutionize mental health diagnoses while ensuring a sustainable revenue stream. By strategically addressing the causes of misdiagnosis, establishing credibility through clinical studies, and targeting key markets, YMI aligns both societal impact and financial success.

 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Corporation believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.